Xponance’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Xponance’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-26,348	Closed	-$23.3K	–	1266
2022 Q4	$23.3K	Buy	26,348 +5,115	+24%	+$6.79K	﹤0.01%	1211
2022 Q3	$33K	Buy	21,233 +945	+5%	+$2.14K	﹤0.01%	1168
2022 Q2	$41K	Buy	20,288 +6,088	+43%	+$10.5K	﹤0.01%	1166
2022 Q1	$33K	Buy	14,200 +117	+0.8%	+$365	﹤0.01%	1152
2021 Q4	$65K	Buy	14,083 +1,015	+8%	+$6.3K	﹤0.01%	1149
2021 Q3	$100K	Sell	13,068 -1,857	-12%	-$15.7K	﹤0.01%	1139
2021 Q2	$145K	Buy	+14,925	New	+$119K	﹤0.01%	1199

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $177M AUM 286.05% 1-Year Est. Return

Oaktree Capital Management Los Angeles, California $5.91B AUM 42.97% 1-Year Est. Return

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

Crescent Grove Advisors Lake Forest, Illinois $1.01B AUM 17.78% 1-Year Est. Return

Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return